PGPIPN vs Dulaglutide
Side-by-side comparison of key properties, dosing, and research.
Immune Support
PGPIPNGLP-1 / Weight Loss Agonists
Dulaglutide- Summary
- PGPIPN is a bioactive hexapeptide (Pro-Gly-Pro-Ile-Pro-Asn) derived from beta-casein during enzymatic digestion. It exhibits anti-inflammatory properties via opioid receptor modulation and cytokine suppression, making it relevant for gut health, systemic inflammation, and as a component of casein-derived functional foods.
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Half-Life
- Estimated 30-120 minutes (peptide degradation)
- ~5 days
- Admin Route
- Oral, Subcutaneous (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 200-500 mg per day
- 0.75 mg → 1.5 mg
- Frequency
- Once or twice daily
- Once weekly
- Key Benefits
- Anti-inflammatory effects via cytokine suppression
- Gut mucosal protection and intestinal barrier support
- Opioid receptor modulation for gut motility regulation
- Potential analgesic activity via central and peripheral opioid pathways
- Explored for inflammatory bowel conditions and gut dysbiosis
- Natural origin (food-derived) with favorable safety profile
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Side Effects
- Generally very well-tolerated given food-derived origin
- Theoretical opioid-mediated constipation at high doses
- Rare milk protein allergy in casein-sensitive individuals
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Stacks With
- —
- —